JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blednov, Y. A.
Right arrow Articles by Harris, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blednov, Y. A.
Right arrow Articles by Harris, R. A.

Vol. 304, Issue 1, 30-36, January 2003


Deletion of the alpha 1 or beta 2 Subunit of GABAA Receptors Reduces Actions of Alcohol and Other Drugs

Yuri A. Blednov, S. Jung, H. Alva, D. Wallace, T. Rosahl, P.-J. Whiting and R. Adron Harris

Waggoner Center for Alcohol and Addiction Research and Section of Neurobiology, University of Texas at Austin, Austin, Texas (Y.A.B., S.J., H.A., D.W., R.A.H.); and Neuroscience Research Center, Merck Sharp and Dohme Research Laboratories, Harlow, Essex, United Kingdom (T.R., P.-J.W.).

    Abstract
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Enhancement of the activation of GABAA receptors is a common feature of many sedative and hypnotic drugs, and it is probable that the GABAA receptor complex is a molecular target for these drugs in the mammalian central nervous system. We set out to elucidate the role of the two predominant (alpha 1 and beta 2) subunits of GABAA receptor in sedative drug action by studying mice lacking these two subunits. Both alpha 1 (-/-) and beta 2 (-/-) null mutant mice showed markedly decreased sleep time induced by nonselective benzodiazepine, flurazepam, and GABAA agonist, 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol. The sleep time induced by the beta -selective drug etomidate was decreased only in beta 2 (-/-) knockout mice. In contrast, alpha 1 (-/-) mice were more resistant to the alpha 1-selective drug zolpidem than beta 2 (-/-) or wild-type animals. Knockout mice of both strains were similar to wild-type mice in their responses to pentobarbital. The duration of loss of the righting reflex produced by ethanol was decreased in male mice for both null alleles compared with wild-type mice, but there were no differences in ethanol-induced sleep time in mutant females. Deletion of either the alpha 1 or beta 2 subunits reduced the muscimol-stimulated 36Cl- influx in cortical microsacs suggesting that these mutant mice have reduced number of functional brain GABAA receptors. Our results show that removal of either alpha 1 or beta 2 subunits of GABAA receptors produce strong and selective decreases in hypnotic effects of different drugs. Overall, these data confirm the crucial role of the GABAA receptor in mechanisms mediating sedative/hypnotic effects.

    Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

GABA, acting via GABAA receptors, is the brain's major inhibitory neurotransmitter system in the central nervous system. Because the ability to enhance the ion channel activation of GABAA receptors is a common feature of many sedative and hypnotic drugs, it is probable that the action on the GABAA receptor complex is a molecular target for these drugs in the mammalian central nervous system (Charney et al., 2001). Nevertheless, many of these drugs, including ethanol and pentobarbital, may have multiple sites of action and the importance of specific GABAA receptors in drug action is not clearly defined.

The GABAA receptor has a pentameric structure, which is formed by the coassembly of subunit polypeptides that exist in a large multigene family (McKernan and Whiting, 1996; Barnard et al., 1998). There are at least 16 different members of the GABAA receptor gene family, including 6alpha , 3beta , 3gamma , delta , epsilon , theta , and pi  subunits (Whiting et al., 1999). The largest population of GABAA receptors in the rat brain has a subunit composition of alpha 1beta 2gamma 2, whereas together alpha 2beta 3gamma 2 and alpha 3beta gamma 2/gamma 3 constitute the next most prevalent subtypes (McKernan and Whiting, 1996). GABA affinity is mainly governed by alpha  subunits (Smith et al., 2001), but affinity and efficacy at the benzodiazepine site are influenced by both alpha  and gamma  subunits (McKernan et al., 1995; Buhr et al., 1996; Wingrove et al., 1997) but not beta  subunits (Hadingham et al., 1993). The benzodiazepine site occurs at the interface of an alpha  and a gamma  subunit, with residues in both influencing modulation (Smith and Olsen, 1995). The presence of gamma 2 confers the classical benzodiazepine pharmacology to GABAA receptors (Pritchett et al., 1989). In contrast, beta  subunits control loreclezole and etomidate sensitivity (Stevenson et al., 1995). Mouse strains lacking individual GABAA receptor subunits provide insight regarding the role of GABA receptors. Mice lacking the gamma 2 subunit die shortly after birth (Gunther et al., 1995), whereas mice deficient the gamma 2L (long splice variant) subunit are viable and show small increases in sleep time responses to midazolam and zolpidem, but responses to nonbenzodiazepine agents such as ethanol, etomidate, and pentobarbital are unchanged (Quinlan et al., 2000). beta 3 null mice (-/-) did not show any changes in sleep times after administration of pentobarbital or ethanol, but they were more resistant to etomidate and midazolam (Quinlan et al., 1998). Mice lacking the alpha 6 subunit of the GABAA receptor, which is expressed exclusively in cerebellar granule cells, have no major phenotypic abnormalities (Jones et al., 1997). Mice deficient the delta  subunit are also viable but show attenuated sensitivity to neuroactive steroids and epileptic seizures (Mihalek et al., 1999). Thus, deletion of some of the less abundant GABAA receptor subunits reduces the action of some sedative drugs, but they do not provide evidence for a major role for GABA receptors in actions of many sedatives. It is important to note, however, that the only predominant GABAA subunit that has been deleted is the gamma 2 and this proved lethal.

Recently, mice lacking the most predominant GABAA receptor subunits, alpha 1 and beta 2, were successfully generated (Sur et al., 2001; Kralic et al., 2002). Although the mice lack approximately 60% of the total number of brain GABAA receptors, adult alpha 1 (-/-) and beta 2 (-/-) mice do not display major phenotypic abnormalities or spontaneous seizures. alpha 1 (-/-) mice showed overexpression of the alpha 2 and alpha 3 subunit but lack approximately 40% of the GABAA receptors despite this apparent compensation. In contrast, beta 2 (-/-) mice displayed an equal reduction in all six alpha  subunits and a loss of GABAA receptors of about 50% (Sur et al., 2001).

In this study, we asked how this substantial decrease of benzodiazepine receptors and reduction of expression of different GABA receptor subtypes might affect receptor function by measuring agonist stimulated 36Cl- uptake in brain tissue from these mutant mice. For the behavioral studies, we used the loss of righting reflex and tested a GABAA agonist, 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP), a nonselective benzodiazepine, flurazepam, and alpha 1-selective drug, zolpidem, a beta -selective drug, etomidate, and two drugs with activities on several channels in addition to GABAA, ethanol and pentobarbital.

    Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Animals. Null alpha 1 (-/-) and beta 2 (-/-) allele mice were created using homologous recombination and genotyped as previously described in Sur et al. (2001). Homozygotes of the F2 generation were interbred avoiding any brother-sister mating, and homozygous colonies of alpha 1 (-/-), beta 2 (-/-) and wild-type (+/+) mice were established. In this study, the mice from the F6 to F7 generations of this interbreeding have been used.

All mice were at least 14 to 18 weeks of age at the time of analysis; within each experiment, all mice were of similar age. Mice were grouped housed (3-5 per cage) under a 12-h light/dark cycle (lights on at 7:00 AM) and provided ad lib access to food and water. All experiments were conducted in an isolated behavioral testing room in the animal facility to avoid external distractions. All mice were allowed to recover for at least 1 week between each drug treatment. Each group of mice, however, was not used for more than for two different drugs, and drug testing was randomized. All experiments were approved by the Institutional Animal Care and Use Committee.

Loss of Righting Reflex. Sensitivity to ethanol (Aaper Alcohol and Chemical Co., Shelbyville, KT; 3.4, 3.6, and 3.8 g/kg, i.p.), flurazepam (Sigma-Aldrich, St. Louis, MO; 225.0 mg/kg, i.p.), zolpidem tartrate (gift from Dr. J. S. Vedo; Pharmacia, Skokie, IL; 60.0 mg/kg, i.p.), pentobarbital (Sigma/RBI, Natick, MA; 50.0 mg/kg, i.p.), etomidate (40.0 mg/kg, i.p.), and THIP (Sigma/RBI; 55.0 mg/kg, s.c.) was determined using the standard sleep time assay (Kakihana et al., 1966). Ethanol was diluted in 0.9% saline (20.0% w/v) and administered in doses adjusted by injected volumes. Flurazepam, zolpidem, and etomidate were dissolved in 3 to 4 drops of Tween 80 (Sigma-Aldrich) before saline was added and injected at 0.01 ml/g b.wt. Pentobarbital was dissolved in 0.9% saline and injected at 0.01 ml/g b.wt. THIP was dissolved in 0.9% saline and injected at 0.005 ml/g b.wt.

All sleep time experiments were performed between 9:00 AM and 1:00 PM. Mice were injected with the drug, and when they became ataxic, they were placed in the supine position in V-shaped plastic troughs until they were able to right themselves three times within 30 s. Sleep time was defined as the time from being placed in the supine position until they regained their righting reflex. During all sleep time assays, room temperature was 24°C. Mice that failed to lose the righting reflex (misplaced injections) or had a sleep time greater than two standard deviations from the group mean were excluded from the analysis unless otherwise noted.

36Cl- Uptake. The procedure was carried out according to Allan and Harris (1986). Animals were killed by decapitation, and their brains were removed and placed in ice-cold buffer (145 mM NaCl, 5 mM KCl, 1 mM MgCl2, 10 mM glucose, 1 mM CaCl2, and 10 mM HEPES; adjusted to pH 7.5 with Tris base). The brain was homogenized by hand (10-12 strokes) using a glass-Teflon homogenizer (size C; Thomas Scientific, Swedesboro, NJ) in 5 ml of ice-cold assay buffer. The homogenate was centrifuged at 900g for 15 min. The supernatant was decanted, and the pellet was washed with 10 ml of assay buffer and centrifuged at 900g for 15 min. The final pellet was suspended in ice-cold assay buffer. Aliquots (0.2 ml) of membrane vesicles (0.6-0.8 mg of protein) were incubated for 5 min in a shaking water bath at 30°C. After this incubation, uptake was initiated by the addition of 0.2 ml of 36Cl- (2 mCi/ml assay buffer) (specific activity 12.8 mCi/g of Cl; obtained from ICN, Irvine, CA) containing 1 to 20 µM muscimol (final concentration). Three seconds after the addition 36Cl- influx was terminated by the addition of 4 ml of ice-cold assay buffer containing 100 µM picrotoxin, and rapid filtration under vacuum (10 mm Hg) onto a Whatman GF/C glass microfiber filter (Whatman, Clifton, NJ) using a Hoeffer manifold (Hoefer Scientific, San Francisco, CA) was performed. The filters were washed with an 8-ml assay buffer containing 100 µM picotoxin with the manifold towers removed. The amount of radioactivity on the filters was determined by liquid scintillation spectrometry. The amount of 36Cl- bound to the filter in the absence of membranes (no tissue blank) was subtracted from all values. Muscimol-dependent influx was defined as the amount of 36Cl- taken up while muscimol was present minus the amount of 36Cl- taken up in the absence of muscimol. The apparent potency (EC50) and apparent efficacy (Emax) of muscimol was determined by the construction of a dose-response curve using five concentrations of the drug. The modulation of muscimol-stimulated 36Cl- uptake by ethanol (25 mM), pentobarbital (25 µM), and flunitrazepam (0.1 µM) was determined by comparing 36Cl- uptake in solutions of each different type of drug containing 36Cl- and 0.65 µM of muscimol for wild-type (+/+) cortex and 36Cl- and 1.0 µM of muscimol for cortex from alpha 1 (-/-) and beta 2 (-/-) null mutant mice with solutions containing only 36Cl- and the corresponding muscimol concentrations for each genotype. These concentrations of muscimol induced a similar stimulation of uptake in all three genotypes. Net uptake was defined as the amount of 36Cl- uptake in the presence of muscimol, corresponding to each genotype concentration, plus the drug tested minus the 36Cl- uptake in the presence of muscimol alone.

Data Analysis. The results are expressed as mean ± S.E.M. The data are reported in minutes for sleep time. For 36Cl- uptake studies, Emax was determined from the dose-response data as the change in 36Cl- flux at the maximally effective concentration, and EC50 was determined by linearly transforming the data (sigmoid curve analysis) using the GraphPad computer program (GraphPad Software, Inc., San Diego, CA). Statistical analysis of parameters was made using the Student's t test with Dunnet's correction for multiple comparisons (Winer, 1971) or by two-way ANOVA whenever appropriate. For all statistical comparisons, p <=  0.05 was considered significant.

    Results
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

The duration of loss of righting reflex (sleep time) produced by ethanol was decreased in both null allele males compared with wild-type mice (P < 0.0001, dependence on genotype; P < 0.0001, dependence on dose, two-way ANOVA) (Fig. 1a). The residual response to ethanol was similar in alpha 1 and beta 2 null mutant males. There were no differences in ethanol-induced sleep time in mutant females (Fig. 1b), however. Null allele mice of both strains did not differ from wild-type mice in their responses to pentobarbital (Fig. 1, c and d).


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 1.   Ethanol- and pentobarbital-induced loss of righting reflex in mice lacking the alpha 1 or beta 2 subunit of the GABAA receptor. a and c, show data for males. a, n = 10-12 (+/+); n = 10 alpha 1 (-/-); beta 2 (-/-) = 10 for each dose of ethanol. c, n = 10 for each genotype. b and d, show data for females. b, n = 10-12 (+/+); n = 10 alpha 1 (-/-); beta 2 (-/-) = 10 for each dose of ethanol. d, n = 10 for each genotype. Summary of statistics: a, males showed an effect of genotype (F2,85 = 27.1; P < 0.0001, two-way ANOVA) and dose (F2,85 = 42.1; P < 0.0001, two-way ANOVA). WT, wild-type.

Analysis of flurazepam and THIP-induced loss of righting reflex revealed that alpha 1 (-/-) and beta 2 (-/-) null mutant mice showed markedly decreased sleep time in comparison with wild-type mice (Fig. 2, a and b). Both sexes of mutant mice showed similar changes in response.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 2.   THIP- and flurazepam-induced loss of righting reflex in mice lacking the alpha 1 or beta 2 subunit of the GABAA receptor. a and c, show data for males. a, n = 6 (+/+); n = 7 alpha 1 (-/-); beta 2 (-/-) = 8. c, n = 9 (+/+); n = 8 alpha 1 (-/-) and beta 2 (-/-). b and d, show data for females. b, n = 9 (+/+); n = 7 alpha 1 (-/-); beta 2 (-/-) = 6. d, n = 9 for each genotype. *, p < 0.05; **, p < 0.01; ***, p < 0.001 mutant mice are different from wild-type mice (Student's t test with Dunnet's correction for multiple comparisons). #, p < 0.05; ###, p < 0.001 alpha 1 (-/-) null mutant mice are different from beta 2 (-/-) knockout mice (Student's t test with Dunnet's correction for multiple comparisons). WT, wild-type.

The duration of sleep time induced by etomidate was significantly decreased only in beta 2 (-/-) males (Fig. 3a) and females (Fig. 3b). alpha 1 (-/-) mice of both sexes did not differ from wild-type animals in their sensitivity to etomidate. In contrast, alpha 1 (-/-) mice were more resistant to zolpidem (60 mg/kg) in comparison with wild-type animals (Fig. 3, c and d). There was no difference in resistance to zolpidem-induced sleep time between beta 2 (-/-) and alpha 1 (-/-) females (Fig. 3d). On the other hand, beta 2 (-/-) males showed resistance intermediate between alpha 1 (-/-) null mutant and wild-type males (Fig. 3c).


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 3.   Etomidate- and zolpidem-induced loss of righting reflex in mice lacking the alpha 1 or beta 2 subunit of the GABAA receptor. a and c, show data for males. a, n = 7 (+/+); n = 6 alpha 1 (-/-) and beta 2 (-/-). c, n = 11 (+/+); n = 12 alpha 1 (-/-); n = 13 beta 2 (-/-). b and d, show data for females. b, n = 9 (+/+); n = 10 alpha 1 (-/-) and beta 2 (-/-). d, n = 9 (+/+) and alpha 1 (-/-); n = 12 beta 2 (-/-). *, p < 0.05; **, p < 0.01; ***, p < 0.001 mutant mice are different from wild-type mice (Student's t test with Dunnet's correction for multiple comparisons). ##, p < 0.01; ###, p < 0.001 alpha 1 (-/-) null mutant mice are different from beta 2 (-/-) knockout mice (Student's t test with Dunnet's correction for multiple comparisons). WT, wild-type.

To determine whether the deletion of alpha 1 or beta 2 subunits changed the GABAA receptor function, muscimol-stimulated 36Cl- influx was measured in cortical microsacs. Deletion of either the alpha 1 or beta 2 subunits reduced the response to muscimol (Fig. 4a). The muscimol EC50 was approximately 2-fold higher in both mutant strains than in wild-type mice. The deletion of the beta 2 subunit significantly increased the slope of muscimol response. The maximal effect of muscimol was approximately 25% higher in membranes from wild-type animals compared with the null mutants (Table 1).


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 4.   Effects of deletion of the alpha 1 or beta 2 subunit of the GABAA receptor on muscimol-stimulated chloride flux measured in membranes from cortex. a, n = 11 for each genotype. b to d, n = 12 (+/+); n = 13 alpha 1 (-/-) and beta 2 (-/-). *, p < 0.05 mutant mice are different from wild-type mice (Student's t test with Dunnet's correction for multiple comparisons). #, p < 0.05 alpha 1 (-/-) null mutant mice are different from beta 2 (-/-) knockout mice (Student's t test with Dunnet's correction for multiple comparisons).


                              
View this table:
[in this window]
[in a new window]
 
TABLE 1
Function of GABAA receptors in null mutant mice: parameters of muscimol-stimulated 36Cl- uptake

Values are the mean ± S.E.M. P values refer to statistical differences from wild-type mice (Student t test with Dunnet's correction for multiple comparisons).

Flunitrazepam enhanced muscimol-stimulated 36Cl- uptake equally in microsacs from wild-type and beta 2 null mutant mice. Potentiation of muscimol response by flunitrazepam, however, was significantly higher in membranes from alpha 1 (-/-) mice than from wild-type mice (Fig. 4b). In contrast, there were no differences in potentiation of muscimol response by pentobarbital in the three genotypes (Fig. 4c). Ethanol potentiation of muscimol-stimulated 36Cl- influx was significantly decreased in beta 2 (-/-) mice (Fig. 4d). There were no differences in these ethanol effects between males and females. Ethanol potentiated muscimol-stimulated 36Cl- influx by 1.70 ± 0.16- and 1.69 ± 0.14-fold in wild-type mice, 1.62 ± 0.22- and 1.75 ± 0.23-fold in alpha 1 (-/-) knockout mice, and 1.37 ± 0.07- and 1.15 ± 0.16-fold in beta 2 null mutant mice (males and females, respectively).

    Discussion
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Taken together, these results show that deletion of either the alpha 1 or beta 2 subunits of GABAA receptor reduced the behavioral effects of a wide variety of sedative hypnotic drugs (summarized in Table 2) and indicate that these mutant mice have a reduced number of functional brain GABAA receptors.


                              
View this table:
[in this window]
[in a new window]
 
TABLE 2
Summary of changes in drug-induced loss of righting reflex in alpha 1 and beta 2 null mutant mice

The reductions in sleep time produced by the mutations are generally consistent with biochemical studies of brain and recombinant receptors, indicating that THIP and flurazepam affect most GABAA receptors and thus show similar effects of deletion of either the alpha 1 or beta 2 subunit. For etomidate, subtypes of the beta -subunit influence the potency with which etomidate potentiates GABA-evoked currents and the beta  isoform is a crucial determinant of the GABA-mimetic activity of this compound (Hill-Venning et al., 1997). Concerning the effects of etomidate on recombinant GABAA receptors composed of alpha 1, gamma 2S, and either beta 1, beta 2, or beta 3 subunits, Sanna et al. (1997) showed that the order of potency after application of this drug was beta 3 > beta 2 > beta 1. In accordance with these findings, the loss of righting reflex produced by etomidate was reduced only in the beta 2 mutants not in the alpha 1 knockouts.

Zolpidem has a higher affinity for GABAA receptors containing alpha 1 subunits than for other receptors (Pritchett et al., 1989; Sieghart, 1995), and sleep time produced by this drug was markedly decreased in alpha 1 null mutant mice. Nevertheless, beta 2 knockout mice also showed a significant decrease in zolpidem-induced sleep time. This is perhaps surprising in view of the findings that there was a complete loss of high-affinity binding sites for zolpidem in alpha 1 (-/-) mice, whereas high-affinity zolpidem binding sites still accounted for 49% of total [3H]flumazenil sites in beta 2 (-/-) brains (Sur et al., 2001). It should be noted, however, that at the high doses used to produce loss of righting reflex, it is likely that zolpidem is not completely selective for alpha 1-containing receptors.

In view of the clear changes in action of these GABAergic drugs, it was surprising that pentobarbital sleep time was not altered in the mutant mice, but this is consistent with the robust potentiation by pentobarbital of the GABA current in Purkinje cells isolated from these mutant mice (Sur et al., 2001). In addition, deletion of another beta  subunit, beta 3, also failed to change pentobarbital sleep time (Quinlan et al., 1998). Pentobarbital has effects on a number of other ion channels (Wartenberg et al., 2001; Yamakura et al., 2001; Bachmann et al., 2002), and it is possible that these targets are more important for pentobarbital-induced loss of righting reflex than the GABAA receptor.

Reduction of alcohol sleep time by deletion of either the alpha 1 or beta 2 subunit is consistent with the idea that ethanol enhances GABAA receptor function and thereby produces some of its behavioral effects (Harris, 1999). The effect of the null mutations was only seen in male mice, however, suggesting that females may employ additional mechanisms for production of ethanol effects or that the GABAA receptor action of ethanol is less important in female mice. There is evidence for gender differences in alcohol sleep time and genetic influences upon that behavior (DeFries et al., 1989). In addition, neurosteroids derived from progesterone have been implicated in alcohol actions, including loss of righting reflex (Morrow et al., 2001). Thus, actions of ethanol such as loss of righting reflex likely involve multiple targets, including the GABAA receptor.

Results from GABA receptor function measured in cortical membranes by chloride flux are generally consistent with previous biochemical and current behavioral studies of these mice. In particular, both knockout strains showed decreased maximum stimulation of muscimol-stimulated 36Cl- uptake. Sur at al. (2001) showed that both the alpha 1 (-/-) and beta 2 (-/-) mice demonstrated a large (50-70%) widespread loss of GABAA receptors measured by [35S]t-butylbicyclophosphorothionate and [3H]muscimol binding and of benzodiazepine binding sites measured by [3H]flumazenil binding. Nevertheless, the 25% decrease in chloride flux (Emax) that we observed suggests that mutant mice compensate for loss of receptor subunits by either more efficient trafficking of receptors to the membrane surface or greater function of remaining receptors. In addition to the decrease in Emax, the mutant mice also showed an increased muscimol EC50, likely a consequence of subunit substitution in the remaining receptors. The potency of muscimol varies with the type of alpha  subunit incorporated into the GABAA receptor complex in the order alpha 6 > alpha 5 = alpha 2 > alpha 1 > alpha 3 (Ebert et al., 1997) and substitution of alpha 3 for alpha 1 as a possible explanation for the decreased muscimol EC50 in mutant mice. At first glance, the ability to potentiate the 36Cl- uptake by several different sedatives does not appear consistent with behavioral effects of these drugs. For example, potentiation of muscimol action by flunitrazepam was not changed in beta 2 knockout mice and was increased in alpha 1 null mutant mice, despite decreased sleep times in both mutants. It should be noted, however, that we are measuring flunitrazepam effects on the remaining GABAA receptors; thus, these potentiation values do not reflect the loss of GABA receptors. It appears that the reason for the decrease in behavioral actions of flurazepam is the decrease in number of GABAA receptors, not a change in the properties of the remaining receptors. On the other hand, the increase in flunitrazepam potentiation of muscimol action in alpha 1 null mutant mice could reflect overexpression of alpha 2 and alpha 3 subunits in these mice (Sur et al., 2001). It is known that the benzodiazepine potentiation of GABA action is greater at alpha 3beta 3gamma 2 subunits than at alpha 1 or alpha 5 containing receptors (Smith at al., 2001). In the case of ethanol, however, there is evidence for decreased sensitivity of the remaining receptors, at least in the beta 2 null mutants.

The majority of gene-targeted mice are developed on a mixed genetic background of inbred mouse strains C57BL/6J and strain 129, and it is useful to compare the responses of wild-type and null allele mice to the pattern of responses found in the parental mouse strains used. In the present study, genes linked to the alpha 1 (-/-) and beta 2 (-/-) mutations would be derived from strain 129/SvEv, whereas genes linked to the wild-type alpha 1 and beta 2 genes would stem from C57BL/6J. Two recent articles (Simpson et al., 1997; Threadgill et al., 1997) have shown that there is substantial genetic variation among substrains of 129 inbred strain. There are no available data about effects of sedative drugs in the 129/SvEv substrain. Homanics et al. (1999) found that 129/SvJ and C57BL/6J inbred strains have similar hypnotic responses to ethanol and pentobarbital. 129/SvJ mice, however, are markedly less sensitive to the hypnotic effects of midazolam, zolpidem, and propofol (sleep times 30, 65, and 52% of the C57BL/6J values, respectively), whereas 129/SvJ are significantly less resistant to etomidate (30% greater sleep time than C57BL/6J). Because our data show a decrease of ethanol-induced sleep in alpha 1 (-/-) and beta 2 (-/-) males and of etomidate-induced sleep only in beta 2 (-/-) mice, these effects are most likely the result of mutations and not of flanking genes from the 129/SvEv strain.

Another concern with studies of null mutant mice is compensation (Crawley, 1996; Gerlai, 2001). It is likely that some compensatory changes occur in the brain to allow near normal brain function without alpha 1 or beta 2 subunits. Our data showing only a 25% decrease in the maximal chloride flux through GABAa receptors in the face of a larger loss of receptor density suggests one type of compensation. Interestingly, very similar results were recently obtained from independently generated alpha 1 knockout mice (Kralic et al., 2002).

In conclusion, these data show that removal of either alpha 1 or beta 2 subunits of GABAA receptors produce strong and specific decreases effects of different drugs. Overall, these data confirm the crucial role of the GABAA receptor in mechanisms mediating sedative/hypnotic effects.

    Acknowledgments

We thank Dr. Gregg Homanics for helpful discussions and comments on the experiments.

    Footnotes

Accepted for publication September 11, 2002.

Received for publication August 8, 2002.

This work was supported by funds from the Texas Commission on Alcohol and Drug Abuse and National Institutes of Health/National Institute on Alcohol Abuse and Alcoholism Grants AA06399 and AA13520.

DOI: 10.1124/jpet.102.042960

Address correspondence to: Dr. Yuri A. Blednov, The University of Texas at Austin Waggoner Center for Alcohol and Addiction Research, 1 University Station, A4800 2500 Speedway MBB 1.124, Austin, TX 78712-0159. E-mail: yablednov{at}mail.utexas.edu

    Abbreviations

THIP, 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol; ANOVA, analysis of variance.

    References
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References


0022-3565/03/3041-0030-0036$07.00
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Neurophysiol.Home page
J. Liang, I. Spigelman, and R. W. Olsen
Tolerance to Sedative/Hypnotic Actions of GABAergic Drugs Correlates With Tolerance to Potentiation of Extrasynaptic Tonic Currents of Alcohol-Dependent Rats
J Neurophysiol, July 1, 2009; 102(1): 224 - 233.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Hu, I. V. Lund, M. C. Gravielle, D. H. Farb, A. R. Brooks-Kayal, and S. J. Russek
Surface Expression of GABAA Receptors Is Transcriptionally Controlled by the Interplay of cAMP-response Element-binding Protein and Its Binding Partner Inducible cAMP Early Repressor
J. Biol. Chem., April 4, 2008; 283(14): 9328 - 9340.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
G. Akk, P. Li, B. D. Manion, A. S. Evers, and J. H. Steinbach
Ethanol Modulates the Interaction of the Endogenous Neurosteroid Allopregnanolone with the {alpha}1beta2{gamma}2L GABAA Receptor
Mol. Pharmacol., February 1, 2007; 71(2): 461 - 472.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. F. Werner, Y. A. Blednov, O. J. Ariwodola, Y. Silberman, E. Logan, R. B. Berry, C. M. Borghese, D. B. Matthews, J. L. Weiner, N. L. Harrison, et al.
Knockin Mice with Ethanol-Insensitive {alpha}1-Containing {gamma}-Aminobutyric Acid Type A Receptors Display Selective Alterations in Behavioral Responses to Ethanol
J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 219 - 227.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
H. Einat
Modelling facets of mania - new directions related to the notion of endophenotypes
J Psychopharmacol, September 1, 2006; 20(5): 714 - 722.
[Abstract] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
R. E. Petroski, J. E. Pomeroy, R. Das, H. Bowman, W. Yang, A. P. Chen, and A. C. Foster
Indiplon Is a High-Affinity Positive Allosteric Modulator with Selectivity for {alpha}1 Subunit-Containing GABAA Receptors
J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 369 - 377.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. M. Platt, A. Duggan, R. D. Spealman, J. M. Cook, X. Li, W. Yin, and J. K. Rowlett
Contribution of {alpha}1GABAA and {alpha}5GABAA Receptor Subtypes to the Discriminative Stimulus Effects of Ethanol in Squirrel Monkeys
J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 658 - 667.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
J. W. Maas Jr, S. K. Vogt, G. C. K. Chan, V. V. Pineda, D. R. Storm, and L. J. Muglia
Calcium-Stimulated Adenylyl Cyclases Are Critical Modulators of Neuronal Ethanol Sensitivity
J. Neurosci., April 20, 2005; 25(16): 4118 - 4126.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
P. H. Wu, W. Poelchen, and W. R. Proctor
Differential GABAB Receptor Modulation of Ethanol Effects on GABAA Synaptic Activity in Hippocampal CA1 Neurons
J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 1082 - 1089.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. L. Boehm II, L. Peden, R. A. Harris, and Y. A. Blednov
Deletion of the fyn-Kinase Gene Alters Sensitivity to GABAergic Drugs: Dependence on {beta}2/{beta}3 GABAA Receptor Subunits
J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1154 - 1159.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
Z. Nie, P. Schweitzer, A. J. Roberts, S. G. Madamba, S. D. Moore, and G. R. Siggins
Ethanol Augments GABAergic Transmission in the Central Amygdala via CRF1 Receptors
Science, March 5, 2004; 303(5663): 1512 - 1514.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
J. Y. Sebe, E. D. Eggers, and A. J. Berger
Differential Effects of Ethanol on GABAA and Glycine Receptor-Mediated Synaptic Currents in Brain Stem Motoneurons
J Neurophysiol, August 1, 2003; 90(2): 870 - 875.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
Y. A. Blednov, D. Walker, H. Alva, K. Creech, G. Findlay, and R. A. Harris
GABAA Receptor {alpha}1 and {beta}2 Subunit Null Mutant Mice: Behavioral Responses to Ethanol
J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 854 - 863.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. E. Kralic, M. Wheeler, K. Renzi, C. Ferguson, T. K. O'Buckley, A. C. Grobin, A. L. Morrow, and G. E. Homanics
Deletion of GABAA Receptor alpha 1 Subunit-containing Receptors Alters Responses to Ethanol and Other Anesthetics
J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 600 - 607.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blednov, Y. A.
Right arrow Articles by Harris, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blednov, Y. A.
Right arrow Articles by Harris, R. A.


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition